Medical diagnostics company Omega is part of a consortium that has won a UK Government order for one million COVID-19 lateral flow antibody tests.
The Clackmannanshire-based company is part of the UK Rapid Test Consortium which will help deliver on plans to roll out COVID-19 surveillance studies to help build a picture of how the virus has spread across the country.
The AbC-19 Rapid test uses a small drop of blood from a finger-prick, and shows results in 20 minutes, without the need for a patient sample to be sent to a laboratory.
The test is currently CE-Marked for professional use and can be administered by healthcare professionals, such as doctors, nurses, pharmacists and healthcare workers, at the point-of-care.
The UK-RTC are seeking approval from government watchdog the Medicines and Healthcare products Regulatory Agency for self-test use.
UK-RTC members are in the final stages of formalising an agreement for the supply of goods from members to Abingdon Health, following the Memorandum of Understanding that was signed in April 2020.
Omega expects to manufacture around 175,000 of these first one million tests but over the term of this supply agreement, Omega will manufacture not less than a quarter of the demand from total orders placed, either from the UK Government or, where allowed, third party customers.
The company expects to provide a trading update for the six months to 30 September in late October 2020.
Omega CEO Colin King said: “We believe that the AbC-19 Rapid test has the immediate opportunity to allow the UK to build a swift and clear picture of how the virus has spread throughout the population.
“It also has the potential to be deployed in conjunction with vaccine candidates to help assess initial immune responses.”
Omega’s medical diagnostics work focuses on infectious diseases and food intolerance.